157 related articles for article (PubMed ID: 19738990)
1. Synergistic antitumor effect of TRAIL and adriamycin on the human breast cancer cell line MCF-7.
Cui DD; Huang Y; Mao SH; Chen SC; Qiu M; Ji LL; Yi C
Braz J Med Biol Res; 2009 Sep; 42(9):854-62. PubMed ID: 19738990
[TBL] [Abstract][Full Text] [Related]
2. Essential role of c-Jun-NH2-terminal kinase on synergy induction of apoptosis by TRAIL plus ADM in ADM resistant MCF-7/ADM cells.
Li F; Meng L; Xing H; Zhou J; Wang S; Huang L; Xu G; Zhu H; Lu Y; Ma D
Apoptosis; 2006 Jul; 11(7):1239-46. PubMed ID: 16703262
[TBL] [Abstract][Full Text] [Related]
3. [Synergistic induction of apoptosis by the combination of TRAIL and low dose adriamycin in human osteosarcoma cell line U2OS].
Yang DS; Miao XD; Ye ZM; Xu YS
Zhonghua Zhong Liu Za Zhi; 2005 Oct; 27(10):595-7. PubMed ID: 16438867
[TBL] [Abstract][Full Text] [Related]
4. Death receptor-dependent and -independent pathways in anticancer drug-induced apoptosis of breast cancer cells.
Kim R; Tanabe K; Emi M; Uchida Y; Toge T
Oncol Rep; 2003; 10(6):1925-30. PubMed ID: 14534720
[TBL] [Abstract][Full Text] [Related]
5. [Molecular mechanism of cisplatin to enhance the ability of TRAIL in reversing multidrug resistance in gastric cancer cells].
Zhu X; Zhang K; Wang Q; Chen S; Gou Y; Cui Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):404-11. PubMed ID: 26463141
[TBL] [Abstract][Full Text] [Related]
6. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
[TBL] [Abstract][Full Text] [Related]
7. Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death.
Meslin F; Hamaï A; Gao P; Jalil A; Cahuzac N; Chouaib S; Mehrpour M
Cancer Res; 2007 Nov; 67(22):10910-9. PubMed ID: 18006836
[TBL] [Abstract][Full Text] [Related]
8. [Synergistic effect and its possible mechanisms of lidamycin in combination with TRAIL in NSCLC].
Yang J; Chen SZ
Yao Xue Xue Bao; 2010 Oct; 45(10):1247-53. PubMed ID: 21348302
[TBL] [Abstract][Full Text] [Related]
9. The synergistic effects of low-dose irinotecan and TRAIL on TRAIL-resistant HT-29 colon carcinoma in vitro and in vivo.
Zhu H; Zhao F; Yu S; He J; Deng L; Yi C; Huang Y
Int J Mol Med; 2012 Nov; 30(5):1087-94. PubMed ID: 22922573
[TBL] [Abstract][Full Text] [Related]
10. Synergistic antitumor effect of TRAIL and doxorubicin on colon cancer cell line SW480.
Xu LH; Deng CS; Zhu YQ; Liu SQ; Liu DZ
World J Gastroenterol; 2003 Jun; 9(6):1241-5. PubMed ID: 12800232
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of Death Receptor 5 and Production of Reactive Oxygen Species Mediate Sensitization of PC-3 Prostate Cancer Cells to TRAIL Induced Apoptosis by Vitisin A.
Shin D; Kwon HY; Sohn EJ; Nam MS; Kim JH; Lee JC; Ryu SY; Park B; Kim SH
Cell Physiol Biochem; 2015; 36(3):1151-62. PubMed ID: 26111475
[TBL] [Abstract][Full Text] [Related]
12. [Effect of inhibiting survivin expression with antisense oligodeoxynucleotides on sensitivity of hepatocellular carcinoma cell lines HepG2 and HepG2/ADM to adriamycin].
Dai DJ; Lu CD; Guo JM; Zhang J
Ai Zheng; 2005 Aug; 24(8):951-7. PubMed ID: 16086872
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
[TBL] [Abstract][Full Text] [Related]
14. Tumor Cell-selective Synergism of TRAIL- and ATRA-induced Cytotoxicity in Breast Cancer Cells.
Reinhardt A; Liu H; Ma Y; Zhou Y; Zang C; Habbel JP; Possinger K; Eucker J
Anticancer Res; 2018 May; 38(5):2669-2682. PubMed ID: 29715087
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells.
Wu XX; Kakehi Y; Mizutani Y; Nishiyama H; Kamoto T; Megumi Y; Ito N; Ogawa O
Int J Cancer; 2003 Apr; 104(4):409-17. PubMed ID: 12584736
[TBL] [Abstract][Full Text] [Related]
16. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
[TBL] [Abstract][Full Text] [Related]
17. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Kazhdan I; Marciniak RA
Cancer Gene Ther; 2004 Oct; 11(10):691-8. PubMed ID: 15354201
[TBL] [Abstract][Full Text] [Related]
18. Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5.
Choi SY; Kim MJ; Chung HY; Lee SJ; Jang YJ
Oncol Rep; 2007 Jan; 17(1):175-84. PubMed ID: 17143496
[TBL] [Abstract][Full Text] [Related]
19. The synergistic effect of 2,3,5,4'-Tetrahydroxystilbene-2-O-β-d-glucoside combined with Adriamycin on MCF-7 breast cancer cells.
Shen J; Zhang Y; Shen H; Pan H; Xu L; Yuan L; Ding Z
Drug Des Devel Ther; 2018; 12():4083-4094. PubMed ID: 30555223
[TBL] [Abstract][Full Text] [Related]
20. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP.
Kang J; Bu J; Hao Y; Chen F
Prostate Cancer Prostatic Dis; 2005; 8(3):274-9. PubMed ID: 15897917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
